Research Paper|Volume 16, Issue 1|pp 191—206

Manganese and IL-12 treatment alters the ovarian tumor microenvironment

Yan Xu¹, Xin Huang², Xiao-Cui Nie¹, Yan-Song Liu¹, Yang Zhou³, Ju-Min Niu¹

¹Department of Gynecology, Shenyang Women and Children’s Hospital, Shenyang 110000, China
²Department of General Practice Medicine, Shengjing Hospital Affiliated to China Medical University, Shenyang 110000, China
³Department of Obstetrics and Gynecology, Shengjing Hospital Affiliated to China Medical University, Shenyang 110000, China

Received: August 6, 2023Accepted: November 6, 2023Published: January 3, 2024

https://doi.org/10.18632/aging.205361

Copyright: © 2024 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Metal immunotherapy is a novel adjuvant immunotherapy. Mn²⁺ can activate STING—a type I IFN response protein—that promotes innate immunity and increases anti-tumor activity by promoting macrophage phagocytosis. IL-12, a cytokine that increases the antigen-presenting ability to promote effector T-cell activation, has potent antitumor activity, albeit with severe adverse effects. In this study, we observed that the combination of Mn²⁺ and IL-12 has a better antitumor effect and possibly reflects a better safety profile, providing a novel approach and theoretical basis for safe and rapid cancer treatment.